Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fu-Quan Zhang

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Cancer Medicine|October 26, 2018
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)Bo Chen, Su-Yu Zhu, Mei Shi, et al.
Aging|October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open|March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell LymphomaXin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
American Journal of Hematology|May 26, 2020
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group studyShu-Nan Qi, Yong Yang, Yu-Jing Zhang, et al.
Leukemia|March 11, 2020
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-makingSi-Ye Chen, Yong Yang, Shu-Nan Qi, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancer Medicine|October 26, 2018
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)Bo Chen, Su-Yu Zhu, Mei Shi, et al.
Aging|October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open|March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell LymphomaXin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
American Journal of Hematology|May 26, 2020
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group studyShu-Nan Qi, Yong Yang, Yu-Jing Zhang, et al.
Leukemia|March 11, 2020
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-makingSi-Ye Chen, Yong Yang, Shu-Nan Qi, et al.
Pageof 5